Abstract

ObjectiveThe use of antiretrovirals (ARV) during pregnancy has drastically reduced the rate of the human immunodeficiency virus perinatal transmission (MTCT). As a consequence of widespread ARV use, transmission of drug resistant strains from mothers to their babies is increasing. Ultra-sensitive PCR techniques have permitted the quantification of minority viral populations, but little is known about the transmission of drug-resistant HIV-1 minority population in the setting of MTCT.Methodology/Principal FindingsWe describe the case of a female child born to an HIV-infected mother, which had not taken any ARV during the pregnancy. The child's first genotype demonstrated a minor non-nucleoside reverse transcriptase inhibitor (K101E), and during her treatment with reverse transcriptase and protease inhibitors full resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) emerged (G190A). Phenotypic/genotypic analysis of variant quasispecies through yeast TyHRT assay was conducted to characterize minority resistant viral strains circulating in both mother and child. Maximum likelihood and Bayesian MCMC phylogenetic analyses were performed with samples from the pair to assess genetic relatedness among minor viral strains. The analysis showed that the child received a minor NNRTI resistant variant, containing the mutation K101E that was present in less than 1% of the mother's quasispecies. Phylogenetic analyses have suggested common ancestry between the mother's virus strain carrying K101E with the viral sequences from the child.ConclusionThis is the first documentation of MTCT of a minority resistant strain of HIV-1. The transmission of minor resistant variants carries the threat of emergence of multi-drug primary mutations without identified specific selective pressures.

Highlights

  • This is the first documentation of mother-to-child transmission (MTCT) of a minority resistant strain of HIV-1

  • The use of antiretrovirals (ARV), the combination therapy known as highly active antiretroviral therapy (HAART) during pregnancy, has substantially decreased mother-to-child transmission (MTCT)

  • We have reported here the description of MTCT of a minor HIV-1 variant carrying the nonnucleoside reverse transcriptase inhibitors (NNRTI) mutation K101E

Read more

Summary

Introduction

The use of antiretrovirals (ARV), the combination therapy known as highly active antiretroviral therapy (HAART) during pregnancy, has substantially decreased mother-to-child transmission (MTCT). As a consequence of ARV selective pressure and widespread use, transmission of resistance strains from mothers to their babies is increasing [2]. Vertical transmission of HIV-1 variants resistant to reverse transcriptase inhibitors has been reported and some studies suggest that resistant mutations are selectively transmitted [3,4,5]. No vertical transmission of NNRTI and PI major mutations has been observed, even when representing the predominant maternal variant [5]. Studies using single-dose nevirapine to MTCT prevention suggest that transmission of NNRTI-resistant strains is a rare event, if it occurs at all [6,7]. Transmission of major NNRTI and PI mutations has been rarely reported in infants born to mothers who acquired primary resistance mutations by heterosexual transmission or during the course of their treatment [8,9]. Transmitted resistant mutations can take years to fade away even when the population transmitted is a mixture of wild-type and drug-resistant virus [10]

Methods
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call